Entera Bio Ltd.
$1.34
▲
10.53%
2026-04-21 06:39:01
enterabio.com
NCM: ENTX
Explore Entera Bio Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$62.47 M
Current Price
$1.34
52W High / Low
$3.22 / $0.91
Stock P/E
—
Book Value
$0.28
Dividend Yield
—
ROCE
-83.6%
ROE
-1.08%
Face Value
—
EPS
$-0.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
1.54
Debt / Equity
3.74
Current Ratio
6.94
Quick Ratio
6.94
Forward P/E
-2.09
Price / Sales
1,490.89
Enterprise Value
$47 M
EV / EBITDA
-4.09
EV / Revenue
1,118.99
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 2. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 3. | ProMIS Neurosciences, Inc. | $11.45 | — | $24.63 M | — | 3267.2% | -5.22% | $39.75 / $6.27 | $-0.58 |
| 4. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 5. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 6. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 7. | Bolt Biotherapeutics, Inc. | $5.15 | — | $9.09 M | — | -71.68% | -79.75% | $9.25 / $3.91 | $13.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.04 M | 0.08 M | — |
| Operating Profit | -3.04 M | -3.26 M | -2.67 M | -2.56 M | -2.34 M | — |
| Net Profit | -3.02 M | -3.2 M | -2.66 M | -2.57 M | -2.36 M | — |
| EPS in Rs | -0.06 | -0.06 | -0.05 | -0.05 | -0.04 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.04 M | 0.18 M | 0 M | 0.13 M |
| Operating Profit | -11.53 M | -9.59 M | -8.89 M | -13.02 M |
| Net Profit | -11.44 M | -9.54 M | -8.89 M | -13.07 M |
| EPS in Rs | -0.21 | -0.18 | -0.16 | -0.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.99 M | 9.39 M | 11.77 M | 13.13 M |
| Total Liabilities | 2.89 M | 1.31 M | 1.38 M | 1.37 M |
| Equity | 13.1 M | 8.08 M | 10.39 M | 11.75 M |
| Current Assets | 15.3 M | 8.97 M | 11.26 M | 12.85 M |
| Current Liabilities | 2.2 M | 1.18 M | 1.09 M | 1.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.37 M | -6.82 M | -7.31 M | -12.5 M |
| Investing CF | -0.11 M | -0 M | -0.02 M | -0.1 M |
| Financing CF | 13.71 M | 4.48 M | 6.04 M | 0.01 M |
| Free CF | -7.48 M | -6.82 M | -7.33 M | -12.55 M |
| Capex | -0.11 M | -0 M | -0.02 M | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -7.33% | 31.99% | — | — |
| Profit Margin % | -5271.27% | — | -9754.48% | — |
| Operating Margin % | -5295.58% | — | -9714.18% | — |
| Gross Margin % | 4.97% | — | 24.63% | — |
| EBITDA Margin % | -5270.17% | — | -9666.42% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.